To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
MAC Clinical Research konverterar sin fordran till aktier i Initiator Pharma
Styrelsen för Initiator Pharma A/S, CVR-nr. 37663808, (“Initiator” eller “Bolaget”) har idag beslutat att genomföra en nyemission riktad till MAC Clinical Research Finance Ltd (“MAC”) i samband med MAC:s anmälan om konvertering av fordran den 20 februari.
MAC Clinical Research converts its receivable into shares in Initiator Pharma
The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at MAC Clinical Research Finance Ltd (“MAC”) in connection with MAC’s conversion notice regarding conversion of outstanding receivable on February 20th.
Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021
The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at members of executive management and key management under the long term incentive program for 2021 (“LTI2021-program”) and to conduct a directed buyback of shares in order to sell shares to the board of directors under the LTI2021-program.
Nyemission och riktat aktieåterköp samt försäljning av aktier i samband med det långsiktiga incitamentsprogrammet för 2021
Styrelsen för Initiator Pharma A/S, med organisationsnummer (CVR) 37663808, (“Initiator” eller “Bolaget”) har idag beslutat att genomföra en ökning av aktiekapitalet riktad till ledande befattningshavare och nyckelpersoner under det långsiktiga incitamentsprogrammet för 2021 (”LTI2021-programmet”) samt att genomföra ett riktat återköp av aktier för att sälja aktier till styrelsens ledamöter under LTI2021-programmet.